Fmr LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Fmr LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,824,675 shares of the company’s stock after purchasing an additional 47,075 shares during the quarter. Fmr LLC owned approximately 14.91% of Janux Therapeutics worth $355,475,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in JANX. Plato Investment Management Ltd lifted its stake in Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Amalgamated Bank lifted its holdings in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares in the last quarter. Summit Securities Group LLC purchased a new stake in shares of Janux Therapeutics in the second quarter worth about $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Activity at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were bought at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the purchase, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the sale, the chief executive officer now owns 257,054 shares in the company, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 445,610 shares of company stock worth $20,578,666. 29.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of analyst reports. Leerink Partners began coverage on shares of Janux Therapeutics in a report on Friday, November 22nd. They issued an “outperform” rating and a $79.00 price objective on the stock. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $67.70.

Janux Therapeutics Trading Down 2.5 %

NASDAQ:JANX opened at $45.21 on Friday. The firm has a fifty day simple moving average of $49.81 and a two-hundred day simple moving average of $45.78. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $65.60. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -38.64 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.